Mucosat is the original and reference preparation of chondroitin sulfate with distinct antiinflammatory and hondroprotective properties used for the treatment of osteoarthritis (OA). The purpose of research is to evaluate the efficacy and tolerability of Mucosat by OA patients.
The study included 49 women of average age of 52.4±7.9 years with disease duration of 8.6±5.8 years, at a body mass index of 30.5±4.8 kg/m
Pain dynamics by VAS and WOMAC index was statistically reliable at 3 week, 8 week and 12 week period of research. 18% of patients stop taking NSAIDs at 3 week, 54% were taking NSAIDs 'on demand' up to 8 weeks. Excellent effect was noted by 42%, good - 22%, low - 8% of patients. Undesirable reactions and side effects were not.
Мукосат - оригинальный и референтный препарат хондроитина сульфата с выраженными противовоспалительными и хондропротективными свойствами, применяемый для лечения остеоартроза (ОА). Цель исследования - оценить эффективность и переносимость мукосата у больных ОА. Материал и методы. В исследование вошли 49 женщин, средний возраст 52,4±7,9 года, с длительностью заболевания 8,6±5,8 года, индекс массы тела 30,5±4,8 кг/м
The study proved: Mucosat is effective and safe drug for the treatment of OA.